Quality of life predicts survival in patients with non-small cell lung cancer by Tsai-Chung Li et al.
Li et al. BMC Public Health 2012, 12:790
http://www.biomedcentral.com/1471-2458/12/790RESEARCH ARTICLE Open AccessQuality of life predicts survival in patients with
non-small cell lung cancer
Tsai-Chung Li1,2, Chia-Ing Li3,4,5, Chun-Hua Tseng6, Kuan-Shin Lin6, Sing-Yu Yang1, Chih-Yi Chen7, Te-Chun Hsia8,
Yih-Dar Lee9,10 and Cheng-Chieh Lin3,4,11*Abstract
Background: Patients with non-small cell lung cancer (NSCLC) have a poor prognosis. The objective of this study
was to examine the relationship of EORTC QLQ-C30 and QLQ-LC13 and survival in patients with NSCLC undergoing
different treatments.
Methods: Investigators conducted a health-related quality of life (HRQOL) survey of 488 patients with NSCLC: 162
patients undergoing surgery, 312 patients without surgery, and their survival status was prospectively followed up.
EORTC QLQ-C30 and QLQ-LC13 scores and clinical variables at baseline were analyzed using Cox’s proportional
hazard regression to identify factors that influenced survival.
Results: Median survival of these 474 patients was 9.82 months. After adjustment, emotional functioning scale, and
symptom scales of pain and nausea/vomiting are associated with survival in NSCLC patients with surgery whereas
social functioning scale, and symptom scales for fatigue, appetite loss, and financial problems had a significant
impact on survival in NSCLC patients without surgery. The results of multivariate analysis showed that none of
QLQ-LC13 scales are significant predictors of survival. After simultaneously considering these scales, we found
significant independent predictors of survival were nausea/vomiting (HR = 0.11, 95% CI = 0.02-0.63 for score >0
compared with =0) in NSCLC patients with surgery and appetite loss (HR = 1.77, 95% CI = 1.26-2.49 for score >0
compared with =0) in NSCLC patients without surgery.
Conclusions: HRQOL provides additional predictive information that supplements traditional clinical factors, and is
a new prognostic indicator for survival of NSCLC patients under different treatments.
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Lung cancer (LC) is the leading cause of cancer-associated
mortality worldwide. In 2011, malignant neoplasm was
the number one leading cause of death in Taiwan,
accounting for more than 20% of total deaths [1]. Lung
cancer was ranked as the second most common cancer in
men, accounting for about 21.2% of all cancer deaths, and
was the most common cancer in women, accounting for
about 16.7% of all cancer deaths.
A growing body of research shows that self-perceptions
of health are linked to mortality, even when more objective* Correspondence: cclin@mail.cmuh.org.tw
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reproduction in any medium, provided the orhealth measures, such as morbidity [2,3], social support
[3], and health behaviors [4] are controlled. Health-related
quality of life (HRQOL) and its assessment have become
increasingly important in the field of oncology. HRQOL is
an important aspect of cancer care. It has been acknowl-
edged as an important end point in cancer clinical trials
and clinical practice, along with the traditional end points,
including tumor response rate, disease-free survival, and
overall survival. Several studies have investigated the prog-
nostic factors of patients with lung cancer, and these have
been reported to enable the differentiation of patients with
favorable and adverse prognoses [5-8]; analyses of
advanced non-small cell lung carcinoma treated with
chemotherapy [5] or with radiotherapy [6], of new cases of
all cancer types and treatments [7], and of advanced lunghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been undertaken.
There is an increasing need for the Chinese version
HRQOL instruments for cancer patients due to increas-
ing incidence rates of cancer in Taiwan. Although the
Chinese version of the European Organization for Re-
search and Treatment of Cancer (EORTC) QLQ-C30
and lung cancer-specific (LC-13) scales were available,
their relationships with survival in lung cancer patients
have never been reported. Therefore, the objective of
this study was to examine the relationship of the EORTC
QLQ-C30 and LC-13 scales and survival in Taiwanese




From July 2004 to December 2007, we consecutively con-
tacted NSCLC patients undergoing active chemotherapy,
surgery or post-therapy follow-up in an inpatient setting
or at the outpatient clinic of the Department of Oncology
at China Medical University Hospital and Taichung Veter-
ans General Hospital, two medical centers in central
Taiwan. NSCLC patients in this cross-sectional study
were initially recruited to participate in a known-groups
validation study of the EORTC QLQ-C30 and QLQ-LC13.
The eligibility criteria for inclusion were a clinical diagno-
sis of NSCLC with local, advanced, or metastatic lung
cancer; American Joint Committee on Cancer/Union
International Cancer Center (AJCC/UICC) stages I-IV; the
ability to read, write and speak Mandarin or Taiwanese;
informed consent; and no major disabling medical or psy-
chiatric conditions that would substantially impair cogni-
tive functioning. Patients who declined to participate were
excluded. Patients were instructed to complete the ques-
tionnaires themselves. Patients who had difficulty in com-
pleting the questionnaires were assisted by interviewers
fluent in both Mandarin and Taiwanese. This study was
approved by the Human Research Committee of China
Medical University Hospital. Written informed consent
was obtained from each participant.
Prognostic clinical variables
We abstracted data on tumor characteristics, such as
date of diagnosis, histology, tumor type, stage, and treat-
ment, and patient characteristics like gender, date of
birth and co-morbidity at the time of diagnosis. We only
included those cases with histology being categorized as
NSCLC. Tumor type was categorized as squamous cell
carcinoma, adenocarcinoma, and undifferentiated car-
cinoma. Stage of lung cancer was defined by location
and extent of primary and metastatic tumor involve-
ment. The standard AJCC/UICC system was used for
staging [9]. Stage of lung cancer was differentiated as Ior II, III (a or b), or IV, with the higher stage represent-
ing more advanced disease. Treatment status was classi-
fied as surgery, chemotherapy or post-therapy follow-up.
Usually, NSCLC patients who did not have completely
resected stage IA and IB would receive adjuvant therapy
and NSCLC patients who are not candidates for surgery
or who refuse surgery, curative intent chemotherapy or
radiotherapy is used. Cancer duration was derived by
calculating the difference between the date of entry and
date of diagnosis, using month as the unit.
Instruments
The EORTC QLQ-C30 [10] and QLQ-LC13 [11] were
used. The EORTC QLQ-C30 is a core cancer-specific
questionnaire containing 30 items on patients’ functioning,
global quality of life (QOL), and disease- and treatment-
related symptoms. The QLQ-LC13 is a site-specific ques-
tionnaire consisting of 13 items on lung cancer symptoms
(cough, haemoptysis, dyspnoea, site-specific pain) and its
treatment-related side-effects (sore mouth, dysphagia, per-
ipheral neuropathy, alopecia). Previous study showed that
overall validation results for the Chinese version of the
EORTC QLQ-C30 and QLQ-LC13 confirmed it as a re-
liable and valid questionnaire for assessing lung cancer-
specific HRQOL in Taiwan [12]. Patients receiving
chemotherapy completed questionnaires between the
first cycle of therapy and the end of the 6th cycle. Patients
undergoing surgery completed the surveys between one
and 4 weeks after surgery. Patients free of recurrent dis-
ease completed the questionnaires at a follow-up visit.
Main outcome measure
The primary outcome measure was survival due to any
cause in the months following baseline assessment of
HRQOL. Survival was ascertained by patients’ family mem-
bers through telephone follow-up. For non-respondents,
vital status was assessed by linking to the National Mortal-
ity database through December 31, 2007 using gender,
identification number, and date of birth. For individuals
reported deceased by family members, the date of death
and cause of death were confirmed using the same process.
The precise date of death along with the date of entry was
used to calculate the event time. Those who did not die
were defined as censored and their data were censored on
December 31, 2007.
Statistical analysis
The Cox proportional hazards model was used to assess
the relative risk of survival in terms of the 2 HRQOL
instruments. First, we categorized the scales of the QLQ
C-30 and LC-13 according to their tertiles, and dichoto-
mized the single-item symptom scales. Then, we evalu-
ated the crude risk of survival separately for each scale,
and added age, gender, stages of cancer, treatment type,
Table 1 Baseline characteristics of NSCLC patients stratified by surgery status and their relation to survival time
Variables Surgery (N = 162) Non-surgery (N = 312)
No. (%) No. of deaths (%) HR (95% C.I.) P value No. (%) No. of deaths (%) HR (95% C.I.) P value
Gender
Male 102 (62.96) 26 (25.49) 1.00 206 (66.03) 118 (57.28) 1.00
Female 60 (37.04) 9 (15.00) 0.73 (0.34-1.55) 0.41 106 (33.97) 50 (47.17) 0.63 (0.45-0.88) 0.006
Age (yrs)
<50 32 (19.75) 3 (9.38) 1.00 48 (15.39) 22 (45.38) 1.00
50 ≤ Age < 60 32 (19.75) 6 (18.75) 1.42 (0.36-5.70 0.62 65 (20.83) 34 (52.31) 1.38 (0.81-2.36) 0.24
60 ≤ Age < 70 45 (27.78) 12 (26.67) 2.01 (0.57-7.13) 0.28 91 (29.17) 47 (51.65) 1.24 (0.75-2.05) 0.41
70 ≤ Age < 80 50 (30.86) 11 (22.00) 1.90 (0.53-6.82) 0.33 90 (28.85) 52 (57.78) 1.44 (0.87-2.37) 0.15
≥80 3 (1.85) 3 (100.00) 8.38 (1.69-41.66) 0.009 18 (5.77) 13 (72.22) 2.80 (1.41-5.57) 0.003
Cancer Duration (yrs)
New cases 102 (62.96) 17 (16.67) 1.42 (0.52-3.89) 0.49 135 (43.27) 66 (48.89) 2.30 (1.43-3.70) <0.001
Cancer duration <1 41 (25.31) 13 (31.71) 1.78 (0.63-5.00) 0.27 124 (39.74) 78 (62.90) 2.36 (1.49-3.75) <0.001
Cancer duration ≥1 19 (11.73) 5 (26.32) 1.00 53 (16.99) 24 (45.28) 1.00
Type of Cancer
Adenocarcinoma 100 (61.73) 19 (19.00) 1.00 195 (62.50) 98 (50.26) 1.00
Squamous Cell 51 (31.48) 13 (25.49) 1.17 (0.58-2.38) 0.66 92 (29.49) 55 (59.78) 1.20 (0.86-1.67) 0.28
Other 11 (6.79) 3 (27.27) 3.57 (1.05-12.16) 0.04 25 (8.01) 15 (60.00) 1.14 (0.66-1.96) 0.65
Clinical Stage
IA, IB, IIA, IIB 115 (70.99) 18 (15.65) 1.00 42 (13.46) 12 (28.57) 1.00
IIIA, IIIB 39 (24.07) 12 (30.77) 2.36 (1.13-4.90) 0.02 97 (31.09) 54 (55.67) 4.83 (2.57-9.08) <0.001
IV 8 (4.94) 5 (62.50) 7.44 (2.74-20.20) <0.001 173 (55.45) 102 (58.96) 6.08 (3.30-11.21) <0.001
Primary Tumora
T1 35 (21.74) 5 (14.29) 1.00 23 (7.54) 12 (52.17) 1.00
T2 88 (54.66) 17 (19.32) 1.44 (0.53-3.90) 0.48 81 (26.56) 32 (39.51) 0.83 (0.43-1.61) 0.58
T3 20 (12.42) 7 (35.00) 2.18 (0.69-6.88) 0.18 28 (9.18) 15 (53.57) 1.30 (0.61-2.78) 0.50
T4 18 (11.18) 6 (33.33) 3.21 (0.97-10.58) 0.06 173 (56.72) 105 (60.69) 2.10 (1.15-3.83) 0.02
Regional Lymph Nodesa
N0 104 (67.10) 16 (15.38) 1.00 67 (23.26) 28 (41.79) 1.00
N1 29 (18.71) 8 (27.59) 1.80(0.77-4.22) 0.17 18 (6.25) 7 (38.89) 1.00 (0.44-2.30) 0.99
N2 20 (12.90) 6 (30.00) 3.10(1.21-7.96) 0.02 79 (27.43) 45 (56.96) 2.49 (1.54-4.02) <0.001
N3 2 (1.29) 1 (50.00) 1.60(0.21-12.1) 0.65 124 (43.06) 80 (64.52) 3.69 (2.36-5.76) <0.001
Distant Metastasis
M0 152 (93.83) 29 (19.08) 1.00 139 (44.55) 65 (46.76) 1.00
M1 10 (6.17) 6 (60.00) 3.29 (1.36-7.93) 0.008 173 (55.45) 103 (59.54) 2.12 (1.54-2.92) <0.001
Type of Treatment
Pneumonectomy
No 132 (90.41) 24 (18.18) 1.00
Yes 14 (9.59) 1 (7.14) 0.17 (0.02-1.29) 0.09
Lobectomy/Bilobectomy
No 59 (40.41) 14 (23.73) 1.00
Yes 87 (59.59) 11 (12.64) 0.81 (0.37-1.79) 0.60
Wedge/Segmental resection
No 98 (67.12) 11 (11.22) 1.00
Yes 48 (32.88) 14 (29.17) 2.23 (1.01-4.92) 0.05
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Table 1 Baseline characteristics of NSCLC patients stratified by surgery status and their relation to survival time
(Continued)
Adjuvant Therapy
No 61 (53.04) 10 (16.39) 1.00
Yes 54 (46.96) 8 (14.81) 1.32 (0.52-3.35) 0.56
Chemotherapeutic agentsa
Iressa 25 (9.80) 12 (48.00) 1.00
Navelbine 129 (50.59) 85 (65.89) 1.69 (0.63-4.49) 0.30
Gemzar 2 (0.78) 2 (100.00) 2.57 (1.12-5.88) 0.03
Taxol 68 (26.67) 37 (54.41) 3.48 (0.7-17.29) 0.13
Taxotere 20 (7.84) 6 (30.00) 2.45 (1.03-5.81) 0.04
Other 11 (4.31) 7 (63.64) 3.88 (1.3-11.59) 0.01
Radiotherapy
No 264 (87.42) 138 (52.27) 1.00
Yes 38 (12.58) 22 (57.89) 1.84 (1.16-2.90) 0.009
a: sample size was not equal to 162 due to missing data; CI, confidence interval; NSCLC, non-small cell lung cancer.
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used the continuous variables of the QLQ C-30 and
LC-13 scales to test linear trends. Finally, five models
were examined. In the first model, the relative hazards of
survival of all clinical variables were examined simultan-
eously. In the second model, the functioning scales of the
QLQ C-30 were examined simultaneously by adjusting for
clinical parameters in the first model. In the third model,
the relative hazards of survival were estimated simultan-
eously for symptom scales of QLQ C-30 while considering
all clinical parameters. In the fourth model, the relative
hazards of survival of the symptom scales of the QLQ
LC-13 were examined simultaneously by controlling
for clinical parameters. In the last model, the signifi-
cant scales of the QLQ C-30 and LC-13 in 2–4 models
were examined simultaneously, while including the
relative hazards of survival with the clinical parameters
in the model. Kaplan-Meier estimates were used to ob-
tain the proportion of patients who had an event dur-
ing follow-up for those significant scales of QLQ-C30
and LC-13 in model 5 and log-rank tests were used to
compare whether the survival functions across sub-
groups were different. All analyses were conducted
using SAS, version 9.1 (SAS Institute Inc. Cary NC).
Results
Patient population
Four hundred seventy-eight NSCLC patients (162 receiv-
ing surgery and 312 not receiving surgery) participated
in this study. The socio-demographic and clinical data
and their relationship to survival stratified by surgery
status are presented in Table 1. Age, clinical stage, pri-
mary tumor, regional lymph nodes, distant metastasis,and type of treatment were significantly associated with
survival in both groups. In addition, female was signifi-
cantly associated with longer survival (HR = 0.63, 95%
CI = 0.45-0.88) and cancer duration <1 year was asso-
ciated with worse survival (2.30, 1.43-3.70 for new cases;
2.36, 1.49-3.75 for <1 year) in patients without surgery.
Health-related quality of life and survival
Table 2 shows the results of univariate and multivariate
analyses that examined whether the various QOL-C30
scores were significant for overall survival stratified by
surgery status. After multivariate adjustment for adjust-
ing for age, gender, cancer duration, type of cancer and
cancer clinical stage of TNM, emotional functioning
scale, and symptom scales of pain and nausea/vomiting
are associated with survival in NSCLC patients with sur-
gery whereas social functioning scale, and symptom
scales for fatigue, appetite loss, and financial problems
had a significant impact on survival in NSCLC patients
without surgery. And there existed a significant linear
trend for fatigue scale. For scales of the QLQ-LC13, the
results of univariate analysis showed that the sore mouth
in patients with surgery, and hemoptysis, and dysphagia
scales of the QLQ-LC13 in NSCLC patients without sur-
gery had a significant impact on survival Table 3. The
results of multivariate analysis showed that none of these
scales remained statistically significant after adjustment.
Hierarchical Cox’s proportional hazard models
Table 4 shows the hierarchical Cox’s proportional hazard
models in NSCLC patients with surgery. The results for
model 1 indicated that age, type of cancer, and regional
lymph nodes were significant prognostic factors for survival,
Table 2 Univariate and multivariate Cox’s analyses of baseline EORTC QLQ-C30 for overall survival stratified by surgery
status
Surgery (N = 162) Non-surgery (N = 312)













Physical Functioning (<100 as reference) 81 25 1.00 1.00 225 130 1.00 1.00
=100 81 10 0.52 (0.25-1.09) 0.61 (0.22-1.74) 84 35 0.67 (0.46-0.98)* 0.89 (0.59-1.35)
Role Functioning (<100 as reference) 27 5 1.00 1.00 105 61 1.00 1.00
=100 135 30 1.30 (0.51-3.36) 2.73 (0.66-11.39) 205 105 0.71 (0.52-0.98)* 1.08 (0.75-1.54)
Emotional Functioning (<83.33 as
reference)
62 12 1.00 1.00 122 63 1.00 1.00
83.33≤EFS < 100 44 11 1.29 (0.57-2.92) 3.36 (1.05-10.69)* 85 53 1.15 (0.8-1.66) 1.20 (0.81-1.78)
=100 56 12 1.06 (0.48-2.36) 2.00 (0.67-5.96) 105 52 0.96 (0.66-1.39) 1.11 (0.75-1.66)
Cognitive Functioning (<100 as reference) 84 19 1.00 1.00 163 90 1.00 1.00
=100 78 16 0.82 (0.42-1.59) 1.21 (0.53-2.76) 149 78 1.00 (0.74-1.35) 1.11 (0.79-1.56)
Social Functioning (<100 as reference) 65 16 1.00 1.00 159 94 1.00 1.00
=100 96 19 0.76 (0.39-1.48) 1.41 (0.57-3.53) 151 73 0.57 (0.42-0.78)*** 0.70 (0.50-0.99)*
Global QOL (≤50 as reference) 54 16 1.00 1.00 166 98 1.00 1.00
50 < QLS≤66.67 55 7 0.43 (0.18-1.05) 0.51 (0.17-1.53) 72 40 0.75 (0.52-1.08) 0.90 (0.61-1.32)
>66.67 52 11 0.72 (0.33-1.55) 0.98 (0.34-2.85) 73 29 0.45 (0.29-0.68)*** 0.79 (0.50-1.26)
Fatigue (≤11.12 as reference) 96 15 1.00 1.00 99 46 1.00 1.00
11.12 < FAS≤33.34 36 10 1.65 (0.74-3.67) 1.78 (0.71-4.48) 111 52 1.37 (0.92-2.04) 1.49 (0.98-2.27)
>33.34 30 10 1.83 (0.82-4.06) 1.07 (0.37-3.09) 102 70 2.52 (1.73-3.68)*** 2.00 (1.34-3.00)***
Pain (=0 as reference) 89 19 1.00 1.00 121 68 1.00 1.00
0 < Pain≤22.22 36 5 0.48 (0.18-1.28) 0.20 (0.05-0.78)* 73 34 0.73 (0.49-1.11) 0.82 (0.53-1.29)
>22.22 37 11 0.98 (0.47-2.07) 0.53 (0.19-1.48) 118 66 1.18 (0.84-1.66) 1.02 (0.70-1.47)
Nausea/Vomiting (=0 as reference) 147 31 1.00 1.00 248 124 1.00 1.00
>0 15 4 0.79 (0.28-2.24) 0.10 (0.02-0.56)** 63 43 1.44 (1.02-2.04)* 0.98 (0.66-1.44)
Dyspnoea (=0 as reference) 114 17 1.00 1.00 156 72 1.00 1.00
>0 48 18 1.80 (0.93-3.51) 1.69 (0.70-4.07) 155 96 1.49 (1.10-2.02)* 1.08 (0.77-1.51)
Insomnia (=0 as reference) 93 18 1.00 1.00 154 80 1.00 1.00
>0 68 17 1.29 (0.67-2.51) 1.62 (0.72-3.64) 152 82 0.93 (0.69-1.27) 0.99 (0.71-1.37)
Appetite Loss (=0 as reference) 125 28 1.00 1.00 188 84 1.00 1.00
>0 37 7 0.71 (0.31-1.63) 0.39 (0.13-1.20) 124 84 2.26 (1.66-3.07)*** 1.79 (1.27-2.52)***
Constipation (=0 as reference) 123 23 1.00 1.00 209 103 1.00 1.00
>0 39 12 1.86 (0.92-3.75) 1.41 (0.51-3.92) 102 65 1.38 (1.01-1.88)* 1.12 (0.80-1.57)
Diarrhoea (=0 as reference) 147 31 1.00 1.00 263 136 1.00 1.00
>0 15 4 1.12 (0.40-3.18) 0.49 (0.07-3.27) 48 32 1.25 (0.85-1.84) 1.28 (0.85-1.95)
Financial Difficulties (=0 as reference) 119 23 1.00 1.00 216 103 1.00 1.00
>0 41 11 1.52 (0.74-3.12) 0.84 (0.28-2.55) 94 64 1.83 (1.34-2.51)*** 1.55 (1.08-2.20)*
Adjusted for age, sex, cancer duration, type of cancer and clinical stage (TNM stage).
*:P < 0.05, **:P < 0.01, ***:P < 0.001.
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QLQ C-30 was a strong predictor of subsequent survival,
after adjusting for all other variables in the model (3.36,
1.05-10.69 for a score 83.33-100 compared to ≤83.33). Theresults for model 3 showed that the effect of the QLQ C-30
scales for nausea/vomiting (0.12, 0.02-0.71 for score >0 com-
pared with score of 0) was statistically significant. Because
none of adjusted HR for QLQ-LC13 scale was statistically
Table 3 Univariate and multivariate Cox’s analyses of baseline EORTC QLQ-LC13 for overall survival stratified by
surgery status
Surgery (N = 162) Non-surgery (N = 312)











Dyspnoea (=0 as reference) 82 8 1.00 1.00 107 44 1.00 1.00
>0 79 26 2.03 (0.91-4.51) 1.46 (0.51-4.16) 201 120 1.32 (0.93-1.86) 1.16 (0.80-1.69)
Cough (=0 as reference) 52 10 1.00 1.00 82 43 1.00 1.00
>0 109 24 1.31 (0.63-2.75) 0.80 (0.33-1.91) 230 125 1.19 (0.84-1.69) 0.97 (0.68-1.40)
Hemoptysis (=0 as reference) 146 30 1.00 1.00 261 142 1.00 1.00
>0 15 4 2.23 (0.78-6.37) 3.01 (0.81-11.18) 50 26 1.57 (1.03-2.39)* 1.04 (0.65-1.69)
Sore Mouth (=0 as reference) 154 30 1.00 1.00 278 147 1.00 1.00
>0 7 4 3.59 (1.26-10.20)* 0.87 (0.14-5.48) 33 21 1.16 (0.73-1.84) 1.03 (0.60-1.76)
Dysphagia (=0 as reference) 144 29 1.00 1.00 257 135 1.00 1.00
>0 17 5 1.31 (0.51-3.40) 0.58 (0.15-2.27) 53 32 1.73 (1.18-2.55)** 1.06 (0.68-1.64)
Peripheral Neuropathy (=0 as reference) 108 23 1.00 1.00 213 109 1.00 1.00
>0 53 11 0.86 (0.42-1.77) 1.03 (0.41-2.59) 97 59 1.10 (0.80-1.51) 1.03 (0.73-1.46)
Hair Loss (=0 as reference) 140 29 1..00 1.00 262 137 1.00 1.00
>0 21 5 1.01 (0.39-2.62) 0.32 (0.07-1.44) 47 29 0.99 (0.66-1.47) 1.11 (0.71-1.73)
Chest Pain (=0 as reference) 107 20 1.00 1.00 183 94 1.00 1.00
>0 54 14 1.05 (0.53-2.09) 0.52 (0.21-1.32) 128 73 1.07 (0.79-1.45) 0.97 (0.70-1.34)
Pain in Arm or Shoulder (=0 as reference) 123 25 1.00 1.00 217 114 1.00 1.00
>0 37 9 0.86 (0.40-1.84) 1.19 (0.45-3.14) 93 53 1.20 (0.87-1.67) 0.96 (0.66-1.39)
Other Pain Sites (=0 as reference) 117 26 1.00 193 106 1.00 1.00
>0 41 7 0.60 (0.26-1.39) 0.38 (0.12-1.19) 106 53 1.02 (0.74-1.42) 0.96 (0.67-1.38)
Adjusted for age, sex, cancer duration, type of cancer and clinical stage (TNM stage).
*:P < 0.05, **:P < 0.01, ***:P < 0.001.
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significant scales of the QLQ C-30 were considered simul-
taneously, nausea/vomiting was the only scale with a signifi-
cant effect on survival (0.11, 0.02-0.63 for a score >0
compared to a score of 0) after controlling for all other vari-
ables in the model.
Table 5 shows the hierarchical Cox’s proportional haz-
ard models in NSCLC patients without surgery. The
results for model 1 indicated that gender, age, cancer
duration, type of cancer, regional lymph nodes, and dis-
tant metastasis were significant prognostic factors for
survival, and model 2 showed that social functioning
scale of the QLQ C-30 was a strong predictor of subse-
quent survival, after adjusting for all other variables in
the model (0.70, 0.50-0.99 for a score 100 compared to
<100). The results for model 3 showed that the effect of
the QLQ C-30 scales for appetite loss (1.62, 1.12-2.36
for score >0 compared with score of 0) were significant.
Because none of adjusted HR for QLQ-LC13 scale was
statistically significant, we fit model 5 directly. As model
5 shows, when significant scales of the QLQ C-30 wereconsidered simultaneously, the effects of appetite loss on
survival remained significant (1.77, 1.26-2.49) after con-
trolling for all other variables in the model.
Survival curves
Figure 1 presents Kaplan-Meier survival curves within
subgroups defined by nausea/vomiting scales in NSCLC
patients with surgery and log-rank tests reveal that there
are no difference within subgroups for these 3 scales.
Figure 2 shows Kaplan-Meier survival curves within sub-
groups defined by appetite loss and it is significantly dif-
ferent (p < 0.001).
Discussion
The present study was the first one examining the rela-
tionship between the Chinese version of the EORTC
QLQ-C30 and QLQ-LC13 and all-cause survival while
adjusting for an array of clinical parameters in a sample
of NSCLC patients stratified by surgery status. We
demonstrated that HRQOL measured by the QLQ C-30
was a strong and independent predictor of overall survival
Table 4 Evaluation of the independent contribution of retained baseline variables for each prognostic score in NSCLC
patients with surgery
Surgery HR (95%C.I.)
Variables Model 1 Model 2 Model 3 Model 4
Gender (=Male as reference)
Female 0.90 (0.31-2.66) 1.27 (0.41-3.89) 1.62 (0.56-4.68) 1.86 (0.63-5.56)
Age (yrs) (<50 as reference)
50 ≤ Age < 60 1.54 (0.27-8.91) 1.51 (0.26-8.93) 2.24 (0.37-13.52) 2.55 (0.43-15.11)
60 ≤ Age < 70 3.71 (0.65-21.23) 3.01 (0.48-19.06) 3.88 (0.73-20.71) 3.50 (0.60-20.30)
70 ≤ Age < 80 3.32 (0.57-19.31) 2.84 (0.46-17.65) 3.53 (0.59-20.98) 3.68 (0.63-21.63)
≥80 41.03 (4.84-347.54)*** 55.83 (5.76-541.35)*** 168.87 (13.26-2150.64)*** 283.27 (21.01-3819.27)***
Cancer duration (yrs) (≥1 as reference)
New case 2.12 (0.65-6.92) 2.13 (0.64-7.03) 2.67 (0.70-10.12) 3.34 (0.88-12.63)
Cancer duration <1 2.24 (0.60-8.40) 2.16 (0.55-8.49) 3.71 (0.84-16.41) 4.78 (1.05-21.74)*
Type of Cancer (Adenocarcinoma as reference)
Squamous Cell 1.76 (0.66-4.68) 2.39 (0.86-6.7) 2.57 (0.94-7.02) 3.62 (1.21-10.86)*
Other 5.09 (1.03-25.12)* 6.01 (1.00-35.92)* 8.25 (1.58-43.09)* 6.64 (1.12-39.39)*
Primary Tumor (T1 as reference)
T2 0.84 (0.28-2.50) 1.02 (0.33-3.20) 1.33 (0.43-4.17) 1.47 (0.45-4.81)
T3 0.94 (0.23-3.78) 1.17 (0.29-4.80) 1.38 (0.35-5.48) 1.63 (0.40-6.64)
T4 1.54 (0.35-6.79) 2.55 (0.52-12.56) 4.42 (0.92-21.22) 5.40 (0.99-29.51)
Regional Lymph Nodes (N0 as reference)
N1 2.34 (0.85-6.45) 2.98 (1.02-8.68)* 2.73 (1.01-7.42)* 3.80 (1.34-10.80)*
N2 5.32 (1.70-16.64)** 6.17 (1.88-20.19)** 5.65 (1.68-18.96)** 7.39 (2.15-25.43)**
N3 6.74 (0.51-89.64) 16.60 (0.98-282.16) 4.55 (0.32-65.68) 9.75 (0.62-153.58)
Distant Metastasis (M0 as reference)
M1 1.73 (0.27-11) 1.07 (0.16-7.39) 1.51 (0.23-9.80) 1.79 (0.29-11.21)
QLQ-C30
Emotional Functioning (<83.33 as reference)
83.33≤EFS < 100 3.36 (1.05-10.69)* 2.56 (0.82-7.96)
=100 2.00 (0.67-5.96) 1.17 (0.39-3.56)
Pain (=0 as reference)
0 < Pain≤22.22 0.24 (0.06-1.01)
>22.22 0.83 (0.30-2.25)
Nausea/Vomiting (=0 as reference)
>0 0.12 (0.02-0.71)* 0.11 (0.02-0.63)*
−2 log likelihood 242.88 238.26 228.77 230.68
*:P < 0.05, **:P < 0.01, ***:P < 0.001.
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scales of the QLQ C-30 and QLQ LC-13 separately, the
emotional functioning scale and symptom scales of pain,
nausea/vomiting were strong predictors with regard to
survival in NSCLC patients with surgery whereas the so-
cial functioning scale and symptom scales of fatigue, appe-
tite loss, and financial difficulties of the QLQ C-30 were
strong predictors in NSCLC patients without surgery.
Using goodness of fit as the criterion, items of symptomson the QLQ-C30 were the strongest predictors among
them. None of QLQ-LC13 scales was significant predic-
tors. After simultaneously taking all significant scales of
the QLQ-C30 into account, nausea/vomiting for NSCLC
patients with surgery and appetite loss for NSCLC patients
without surgery were the most informative variables for an
improved prediction of survival, besides the traditional
clinical parameters. These findings suggest that prediction
of the prognosis could be improved by considering these
Table 5 Evaluation of the independent contribution of retained baseline variables for each prognostic score in NSCLC
patients without surgery
Non-surgery HR (95%C.I.)
Variables Model 1 Model 2 Model 3 Model 4
Gender (=Male as reference)
Female 0.53 (0.36-0.79)** 0.57 (0.38-0.85)** 0.52 (0.35-0.78)** 0.55 (0.37-0.82)**
Age (yrs) (<50 as reference)
50 ≤ Age < 60 1.92 (1.08-3.39)* 2.02 (1.15-3.56)* 2.46 (1.38-4.36)** 2.31 (1.3-4.11)**
60 ≤ Age < 70 1.45 (0.86-2.44) 1.47 (0.88-2.47) 1.40 (0.82-2.39) 1.41 (0.84-2.37)
70 ≤ Age < 80 1.80 (1.07-3.03)* 1.91 (1.13-3.24)* 1.93 (1.12-3.32)* 1.94 (1.15-3.29)*
≥80 3.70 (1.73-7.89)*** 4.53 (2.10-9.75)*** 4.65 (2.14-10.08)*** 4.73 (2.19-10.24)***
Cancer duration (yrs) (≥1 as reference)
New case 1.19 (0.69-2.05) 1.05 (0.61-1.82) 1.28 (0.74-2.22) 1.16 (0.66-2.01)
Cancer duration <1 1.79 (1.08-2.97)* 1.70 (1.02-2.82)* 1.62 (0.97-2.69) 1.62 (0.97-2.69)
Type of Cancer (Adenocarcinoma as reference)
Squamous Cell 0.91 (0.62-1.34) 0.93 (0.62-1.37) 0.87 (0.59-1.30) 0.92 (0.62-1.37)
Other 1.20 (0.65-2.20) 1.42 (0.75-2.68) 1.23 (0.63-2.38) 1.23 (0.64-2.36)
Primary Tumor (T1 as reference)
T2 0.57 (0.28-1.16) 0.60 (0.3-1.21) 0.54 (0.27-1.08) 0.54 (0.27-1.1)
T3 1.20 (0.55-2.64) 1.20 (0.54-2.65) 1.19 (0.54-2.64) 1.17 (0.53-2.58)
T4 1.28 (0.67-2.46) 1.32 (0.68-2.55) 1.15 (0.59-2.23) 1.22 (0.63-2.35)
Regional Lymph Nodes (N0 as reference)
N1 1.06 (0.45-2.49) 0.99 (0.42-2.31) 1.12 (0.47-2.66) 1.01 (0.43-2.37)
N2 2.12 (1.24-3.61)** 1.99 (1.17-3.38)* 1.82 (1.05-3.14)* 1.87 (1.09-3.20)*
N3 2.29 (1.34-3.92)** 2.14 (1.26-3.65)** 1.85 (1.06-3.22)* 1.84 (1.06-3.18)*
Distant Metastasis (M0 as reference)
M1 1.54 (1.04-2.28)* 1.52 (1.03-2.25)* 1.37 (0.91-2.07) 1.47 (0.99-2.19)
QLQ-C30
Social Functioning (<100 as reference)
=100 0.70 (0.50-0.99)* 0.73 (0.52-1.03)
Fatigue (≤11.12 as reference)
11.12 < FAS≤33.34 1.19 (0.77-1.86)
>33.34 1.45 (0.92-2.28)
Appetite Loss (=0 as reference)
>0 1.62 (1.12-2.36)* 1.77 (1.26-2.49)**
Financial Difficulties (=0 as reference)
>0 1.43 (0.99-2.06)
−2 log likelihood 1508.53 1490.90 1475.39 1480.24
*:P < 0.05, **:P < 0.01, ***:P < 0.001.
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prognostic variables.
The nausea/vomiting scale in NSCLC patients with sur-
gery and appetite loss in NSCLC patients without surgery
seemed to capture all the prediction after simultaneously
considering all the significant scales of the QLQ-C30 and
QLQ-LC13. The emotional functioning and pain scales in
NSCLC patients with surgery and social functioning,fatigue, and financial difficulties scales in NSCLC patients
without surgery became insignificant, possibly because
they were moderately correlated with significant scales,
and they did not provide new information regarding sur-
vival after these 2 significant items were considered.
Several different aspects of pretreatment HRQOL have
been associated with survival in advanced cancer [13-16],
breast cancer [17-19], lung cancer [5-8], oesophageal cancer
Figure1 Survival curves for the baseline nausea/vomiting scores in NSCLC patients with surgery.
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cer [24]. Even though few studies have been carried out in
lung cancer patients, our results are in agreement with those
in studies of lung cancer patients. Herndon et al. in a study
of 206 patients with advanced NSCLC using the QLQ-C30
and Duke-UNC Social Support Scale, found that in addition
to the cancer type and dyspnoea, the pain scale was a
prognostic factor of survival [5]. Similarly, Langendijk
et al. in a study of 198 patients treated with external
irradiation using the QLQ-C30, observed that globalFigure 2 Survival curves for the baseline appetite loss scores in NSCLQOL was an independent prognostic factor, but the effect
varied as a function of cancer clinical stage in a 3-year fol-
low-up [6]. Montazeri et al. using the Nottingham Health
Profile, the QLQ-C30 and the QLQ-LC13, reported that
the global QLQ of the QLQ-C30, along with age and ex-
tent of disease, were the significant predictors of 3-month
survival in 129 newly diagnosed lung cancer patients [7].
Recently, Dharma-Wardene et al. using the Functional
Assessment of Cancer Therapy-General (FACT-G), found
that the baseline FACT-G total score was a significantC patients without surgery.
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advanced lung cancer planning to undergo palliative
chemotherapy [8].
Previous studies indicated that pre-treatment HRQOL
is a significant factor for survival time, and pre-
treatment assessment of HRQOL could help physicians
in their clinical decisions, as it directly relates to patients’
survival time. Our finding is that cross-sectional HRQOL
of all treatment types is also a significant factor for sur-
vival outcome, and this has important implications: the as-
sessment of HRQOL in lung cancer patients should be
integrated into clinical practice and evaluated periodically
to adequately monitor the outcome of any resulting treat-
ment or regular follow-up visits. In addition, the inde-
pendent prognostic value of the QLQ-C30 scales for these
patients suggests that a better HRQOL score, reflecting
fewer symptoms of appetite loss would result in better
overall survival in NSCLC patients. In our opinion, one of
the therapeutic goals of HRQOL is to facilitate communi-
cation between patients and doctors, and help doctors
provide care based on patients’ symptoms with the aim of
improving overall survival by controlling the impact of
disease and preserving or improving HRQOL.
The major strengths of our study are that all of the
HRQOL data were available at baseline, with a less than
5% missing rate. The clinical characteristics of these
patients were similar to those of the entire population of
our clinical settings. A high standard of follow-up was
applied, resulting in a low rate of loss to follow-up, a
large number of events, and adequate overall statistical
power. Furthermore, HRQOL was assessed using multi-
dimensional QOL, which would be more informative
than global QOL.
Our results should be interpreted with caution because
of 5 limitations. One limitation is that some of deaths
could not be confirmed through follow-up phone calls
and had to be confirmed through linking with the Na-
tional Mortality database. The death status of some
patients with a missing identification number could not
be confirmed. With only a few cases being lost to
follow-up and with few missing identification numbers,
the error should be small. Another potential drawback is
that the analyses only considered baseline HRQOL; the
relationship between changes in HRQOL measures and
survival could not be examined. Future studies should
focus on how the changes in HRQOL measures relate to
survival due to any causes. Third, the study lacked infor-
mation regarding pulmonary function, comorbidity, gen-
etic factors and the physical environment of these
patients; hence, we cannot rule out the possibility that
our findings may be confounded due to these unmeas-
ured variables. Fourth, due to limited number of sample
size, we could not examine the relationship between
HRQOL and survival in small cell lung cancer patients.Last, this study did not establish a causal relationship
between HRQOL and survival, since an unidentified fac-
tor may have been involved. HRQOL may reflect a
patient’s status of disease, which has a direct effect on a
patient’s survival.
Conclusion
In conclusion, our findings from this study support the
use of HRQOL assessment in routine clinical practice in
a NSCLC patient population. Although the data were
prospectively collected, the findings are limited by the
cross-sectional assessment of HRQOL. Further studies
incorporating longitudinal HRQOL assessment together
with clinical prognostic factors may provide additional
information that may aid the patient and clinician in
decision-making in NSCLC.
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